Ascorbic acid (vitamin C)
synthetic
MECHANISM CLAIMED
At ordinary dietary levels, prevents scurvy. At the multi-gram 'megadose' levels Pauling promoted, claimed to prevent and shorten the common cold via enhanced immune function, and, at very high intravenous doses, to selectively damage cancer cells (via hydrogen-peroxide generation and effects on collagen/hyaluronidase) while sparing normal tissue, prolonging survival in terminal cancer.
MECHANISM ACTUAL
Ascorbic acid is an essential nutrient whose only well-established deficiency disease is scurvy. A 2013 Cochrane systematic review (Hemilä & Chalker) found regular megadose supplementation does not reduce common-cold incidence in the general population (pooled risk ratio 0.97, 95% CI 0.94-1.00), though it modestly shortens cold duration. Two Mayo Clinic randomized, double-blind, placebo-controlled trials (Creagan et al. 1979; Moertel et al. 1985) found no survival or symptom benefit from high-dose oral vitamin C in advanced-cancer patients. The National Cancer Institute's PDQ summary (last revised 28 May 2024) states the FDA has not approved high-dose vitamin C for any medical condition and that human evidence for an anti-cancer effect remains unestablished, even for the intravenous route, which does reach much higher plasma concentrations than oral dosing.
INTERVENTIONS USING IT
EXTERNAL REFERENCES
NOTES
Vitamin C is a genuine essential nutrient whose only confirmed deficiency disease, scurvy, made it one of the first vitamins discovered and synthesized at industrial scale. The megadose claims this case documents — that gram-scale, far-above-dietary doses could prevent the common cold or cure cancer — are a distinct, later claim layered onto that real biochemistry, tested directly in randomized trials, and not supported by them.